M 281

Drug Profile

M 281

Alternative Names: anti-FcRn monoclonal antibody - Momenta Pharmaceuticals; M281

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 06 Jan 2017 Immunogenicity data from a phase I trial in Autoimmune disorders (In volunteers) released by Momenta Pharmaceuticals (Parenteral)
  • 19 Dec 2016 M 281 is available for licensing as of 19 Dec 2016. http://www.momentapharma.com
  • 09 Jun 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in Netherlands (Parenteral) (9197556; NCT02828046)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top